EP Patent

EP4299055A1 — Oral dosage formulations comprising empagliflozin

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2024-01-03 · 2y expired

What this patent protects

The present invention relates to oral dosage formulations comprising Empagliflozin or a pharmaceutically acceptable salt thereof and at least one filler wherein Empagliflozin or pharmaceutically acceptable salt has a d (0.9) particle size higher than 150 µm.

USPTO Abstract

The present invention relates to oral dosage formulations comprising Empagliflozin or a pharmaceutically acceptable salt thereof and at least one filler wherein Empagliflozin or pharmaceutically acceptable salt has a d (0.9) particle size higher than 150 µm.

Drugs covered by this patent

Patent Metadata

Patent number
EP4299055A1
Jurisdiction
EP
Classification
—
Expires
2024-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.